Reduced-Dose Antimicrobial Therapy for Clostridium difficile Infection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Clostridium difficile infection (CDI) often result in high recurrence rates due to disruption of the intestinal flora, with standard antibiotic regimens being ineffective in preventing relapse and potentially causing adverse events.
Innovation Solution
Administering lower doses and shorter courses of antimicrobial agents such as vancomycin, fidaxomicin, metronidazole, and nitazoxanide to treat CDI, which preserves the normal gut flora and immunologic response, reducing recurrence and adverse effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard antibiotic regimens are used to treat CDI, then the infection is effectively treated, but recurrence rate increases due to disruption of intestinal flora
Solution Approach 1:
The patent uses partial action by administering antibiotics at reduced doses that are sufficient to treat the infection but insufficient to cause complete eradication of all bacteria. This partial antibiotic exposure maintains therapeutic efficacy while allowing beneficial intestinal flora to survive and prevent recurrence
2Reliability
If prolonged antibiotic courses are administered, then treatment completeness is improved, but adverse events and disruption of gut flora increase
Solution Approach 1:
The patent employs periodic action through structured treatment protocols with specific durations (10 days for vancomycin, 10 days for fidaxomicin) followed by discontinuation. This periodic administration provides sufficient treatment to complete the infection control while allowing intervals for gut flora recovery, thereby reducing adverse events
Solution Approach 2:
The patent changes the temporal parameter of treatment by optimizing the duration to exactly 10 days based on clinical trial data showing this duration achieves cure without excessive flora disruption. This parameter optimization balances treatment completeness with minimization of adverse effects
3Reliability
If high doses of antibiotics are used, then bacterial eradication is improved, but preservation of normal flora and immunologic response deteriorates
Solution Approach 1:
The patent applies parameter changes by reducing the dosage parameter from standard high doses to optimized lower doses. Clinical data in the patent demonstrates that vancomycin 125mg daily and fidaxomicin 200mg twice daily achieve bacterial eradication while preserving gut flora composition and immunologic response, unlike higher standard doses
Data Source
AI summary
C. difficile infection (CDI) is the most common cause of antibiotic-associated diarrhea. Unfortunately, antibiotic therapy remains as the standard treatment for this antibiotic-induced disease and relapses are common. Antibiotic treatment typically is given for 10 to 14 days for initial or second episode of CDI. For recurrent episodes, more prolonged courses are recommended. It is disclosed herein that lower dose or shorter course of the antimicrobial treatment is sufficient to treat the disease and prevent recurrent disease by enabling a good immunologic response to infection, and perhaps also by better preserving normal flora, thus protecting against relapses or reinfection.